Protocol Ledger

NCT06936566 · Phase II · RECRUITING

MAGIC Ruxolitinib for aGVHD

Interventional Phase II clinical trial protocol NCT06936566 sponsored by John Levine in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-14 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06936566
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06936566
Protocol FieldVerified Registry Value
NCT IdentifierNCT06936566
Consolidated Lead SponsorJohn Levine
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2025-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI